Drugs / Lupartumab Amadotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02134197 | May 2014 → Aug 2018 | neoplasm | Bayer | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lupartumab Amadotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02134197 ↗ |
| Known as | BAY1129980 | “Lupartumab Amadotin (BAY1129980)” NCT02134197 ↗ |
| Modality | Monoclonal antibody | “a fully human C4.4A-targeting mAb” PMID 28292941 ↗ Mar 2017 |
| Route | Intravenous | “intravenous (I.V.) administration” NCT02134197 ↗ |
| Target | LYPD3 | “Anti-C4.4A (LYPD3) Antibody-Drug Conjugate” PMID 28292941 ↗ Mar 2017 |